What the FDA labels say about taking them together
Nirmatrelvir/ritonavir and tofacitinib
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names tofacitinib in its drug interactions section; the tofacitinib label PlainMeds reads does not name nirmatrelvir/ritonavir. The nirmatrelvir/ritonavir label: “Dosage adjustment of tofacitinib is recommended. Refer to the tofacitinib prescribing information for more information.”
Check it at the source: the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc); the tofacitinib FDA label on DailyMed (effective July 13, 2026, U.S. Pharmaceuticals).
What does the nirmatrelvir/ritonavir label say about tofacitinib?
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: Janus kinase (JAK) inhibitors; Drugs within Class: tofacitinib; Effect on Concentration: ↑ tofacitinib; Clinical Comments: Dosage adjustment of tofacitinib is recommended. Refer to the tofacitinib prescribing information for more information.
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
What does the tofacitinib label say about nirmatrelvir/ritonavir?
Tofacitinib's label (effective July 13, 2026) does not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (XELJANZ), NDA203214 (Pf Prism Cv), as published by U.S. Pharmaceuticals, effective July 13, 2026 (SPL set 68e3d6b2-7838-4d2d-a417-09d919b43e13), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Nirmatrelvir/ritonavir | Tofacitinib | |
|---|---|---|
| Labeled for | COVID-19 | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $49.24 per unit 300-100 mg dose pack | $0.573 per tablet 5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once